MedNet EC-REP GmbH Successfully Renews ISO 13485:2016 Certification
We are pleased to announce that MedNet EC-REP GmbH has successfully renewed its ISO 13485:2016 certification, demonstrating our continued commitment to maintaining the highest standards in quality management for medical devices.
The ISO 13485:2016 certification is an internationally recognized standard that sets stringent requirements for quality management systems. This renewal confirms that MedNet EC-REP GmbH remains as a reliable and trusted European Authorized Representative for medical device manufacturers around the world.
At MedNet EC-REP, we pride ourselves on our meticulous approach to regulatory compliance and our unwavering focus on quality assurance. This certification not only validates the effectiveness of our internal processes but also underscores our dedication to helping our clients navigate the complex regulatory environment of the European market.
The renewal of our ISO 13485:2016 certification also highlights the hard work and commitment of our entire team. Their expertise, attention to detail, and continuous improvement mindset enable us to consistently provide the highest level of service to our clients. We remain committed to staying ahead of industry developments and regulatory changes to ensure that our clients are always compliant and well-prepared for market success.
By choosing MedNet EC-REP GmbH as your European Authorized Representative, you can trust that your business is supported by a team that prioritizes quality, compliance, and regulatory excellence. We look forward to continuing our partnership with medical device manufacturers globally, ensuring their products meet all necessary requirements for European market access.
For more information on our services or to learn how we can assist your business, feel free to contact us today.
Latest news
MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.
EUDAMED’s first four modules become mandatory on 28 May 2026 - what this means for medical device manufacturers
The European Commission (EC) has formally declared that the first four modules of EUDAMED - the European Database on Medical Devices - will become mandatory as of 28 May 2026.
MedNet EC-REP GmbH to Exhibit at WHX 2026 in Dubai
MedNet EC-REP GmbH is excited to announce its participation in WHX 2026, taking place from February 9–12 in Dubai. As a trusted European Authorized Representative and compliance partner for global medical device manufacturers, we look forward to presenting our comprehensive regulatory services to an international audience.
Implications of the Update to the Borderline & Classification Manual under MDR and IVDR
On 12 September 2025, the European Commission published Version 4 of the Manual on Borderline and Classification under Regulations (EU) 2017/745 and 2017/746, developed by the Borderline and Classification Working Group (BCWG).
Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR
European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH at MEDICA 2025 – Visit Us in Hall 3, Booth D43
MedNet EC-REP GmbH is pleased to announce that we will once again be exhibiting at MEDICA 2025 in Düsseldorf, the world’s leading trade fair for the medical technology industry.
EU eIFU Regulation Update Draft: What Medical Device Professionals Need to Know
The European Commission has introduced a significant amendment to Implementing Regulation (EU) 2021/2226, impacting how medical device manufacturers provide instructions for use (IFU).
Understanding the Interplay: MDR, IVDR, and the AI Act – Key Insights from MDCG 2025-6
Recently, the MDCG, in conjunction with the Joint Artificial Intelligence Board (AIB), released the MDCG 2025-6 FAQ document, offering essential clarifications on the interplay between the MDR, the IVDR, and the Artificial Intelligence Act (AIA).